Safety
-
Ditropan (oxybutynin chloride) Tablets and Syrup
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- February 2008
| The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. |
Sections Modified
PRECAUTIONS
- Central Nervous System Effects
- Oxybutynin is associated with anticholinergic central nervous system (CNS) effects. A variety of CNS anticholingeric effects have been reported...
- Ditropan should be used with caution in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.
ADVERSE REACTIONS (see highlighted section)
- The following adverse events were reported by 1 to <5% of patients using Ditropan (5 - 20 mg/day):
- Infections and Infestations
- Metabolism and Nutrition Disorders
- Psychiatric Disorders
- Nervous System Disorders
- Eye Disorders
- Cardiac Disorders
- Vascular Disorders
- Respiratory, Thoracic and Mediastinal Disorders
- Gastrointestinal Disorders
- Skin and Subcutaneous Tissue Disorders
- Musculoskeletal and Connective Tissue Disorders
- Renal and Urinary Disorders
- General Disorders and Administration Site Conditions
- Investigations
- Injury, Poisoning, and Procedural Complications
- Postmarketing Surveillance
- Psychiatric Disorders
- Nervous System Disorders
- Eye Disorders
- Cardiac Disorders
- Gastrointestinal Disorders
- Skin and Subcutaneous Tissue Disorders
- Renal and Urinary Disorders
- Reproductive System and Breast Disorders
-
-







